August 2023: Kune metastatic colorectal cancer (mCRC) yakatorapwa nefluoropyrimidine, oxaliplatin, uye irinotecan-based chemotherapy, anti-VEGF biological therapy, uye kana RAS yemusango-rudzi, anti-EGFR therapy, iyo Food and Drug Administration yakabvumidza. trifluridine uye tipiracil (LONSURF, Taiho Oncology, Inc.). LONSURF, mushonga wemumiririri mumwechete, wakatowana mvumo yeFDA yekushandisa iyi munaGunyana 2015.
Mu SUNLIGHT (NCT04737187), yakasarudzika, yakavhurika-label, multicenter, yepasirese kuyedza ichienzanisa LONSURF nebevacizumab kune imwechete-ajenti LONSURF mu492 varwere vane metastatic colorectal cancer avo vakagamuchira inokwana maviri ekutanga chemotherapy regimens uye vakaratidza kufambira mberi kwechirwere chavo kana kusashivirira kune yekupedzisira regimen, kuchengeteka uye kushanda kwakaongororwa.
Kupona kwese (OS) uye kufambira mberi-kusina kupona (PFS) ndiwo aive akakosha emhedzisiro metrics. Varwere vakagoverwa kuLONSURF pamwe chete bevacizumab ruoko rwemuyedzo rwakaratidza kuwedzera kwakakosha kweOS kana ichienzaniswa nevarwere vakapihwa ruoko rweLONSURF (Hazard ratio 0.61; 95% CI: 0.49, 0.77; 1-sided p0.001). Iyo yepakati OS yeLONSURF plus bevacizumab ruoko yaive mwedzi gumi nesere (10.8% CI: 95, 9.4) uye yeLONSURF ruoko yaive mwedzi 11.8 (7.5% CI: 95, 6.3). MuLONSURF pamwe nebevacizumab ruoko, iyo yepakati PFS yaive mwedzi mishanu. CI: 8.6, 5.6 95-sided p4.5).
Neutropenia, anemia, thrombocytopenia, kuneta, kuda kusvotwa, kuwedzera AST, kuwedzera ALT, kuwedzera alkaline phosphatase, kuderera kwesodium, manyoka, kusagadzikana mudumbu, uye kuderera kwechido ndizvo zvinowanzoitika zviitiko zvepadivi kana marabhoritari abnormalities yeLONSURF ine bevacizumab (20%).
Pamazuva 1 kusvika ku5 uye mazuva 8 kusvika ku12 ega ega 28-zuva kutenderera, iyo yakakurudzirwa dhizeti yeLONSURF ndeye 35 mg/m2 inotorwa nemuromo kaviri zuva nezuva nechikafu. Kuti uwane ruzivo nezve bevacizumab dosage, bvunza ruzivo rwekuraira.
Wona ruzivo rwakazara rwekutemerwa kweLONSURF.
